|Videos|June 27, 2023
Navigating and Overcoming Challenges of PSMA-PET Imaging Results Interpretation
Experts share potential solutions to overcome the clinical challenges of using PSMA-PET in practice, including use of reader training programs.
Advertisement
Episodes in this series
Advertisement
Related to this article
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Topline results from the study are anticipated in the first half of 2027.
JNJ-6143 demonstrated promising PSA and tumor response rates with an encouraging safety profile in heavily pretreated mCRPC, including across genomic subgroups.
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Updated CAPItello-281 data showed a clinically meaningful benefit in OS when capivasertib was added to abiraterone and ADT in PTEN-deficient mHSPC.
In TALAPRO-3, talazoparib plus enzalutamide improved rPFS vs placebo plus enzalutamide (HR, 0.48; P < .0001) in HRR-mutated mAPMN/S prostate cancer.
Interim phase 3 data show a 58% reduction in the risk of metastasis or death with the addition of darolutamide to ADT + radiation.
Advertisement
Advertisement
Trending on Urology Times
1
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
2
Updated CAPItello-281 data show numerical OS benefit with capivasertib in PTEN-deficient mHSPC
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
LITESPARK-012: Lessons from a negative phase 3 trial in first-line RCC
5